Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) Invested Capital (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Invested Capital data on record, last reported at $118.3 million in Q3 2025.

  • For Q3 2025, Invested Capital fell 4.79% year-over-year to $118.3 million; the TTM value through Sep 2025 reached $118.3 million, down 4.79%, while the annual FY2024 figure was $117.4 million, 8.48% down from the prior year.
  • Invested Capital reached $118.3 million in Q3 2025 per UTMD's latest filing, up from $117.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $128.3 million in Q4 2023 and bottomed at $104.9 million in Q1 2021.
  • Average Invested Capital over 5 years is $116.1 million, with a median of $117.4 million recorded in 2024.
  • Peak YoY movement for Invested Capital: rose 14.34% in 2023, then fell 8.48% in 2024.
  • A 5-year view of Invested Capital shows it stood at $107.1 million in 2021, then increased by 6.64% to $114.3 million in 2022, then rose by 12.3% to $128.3 million in 2023, then dropped by 8.48% to $117.4 million in 2024, then grew by 0.7% to $118.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $118.3 million in Q3 2025, $117.5 million in Q2 2025, and $117.0 million in Q1 2025.